Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial

Yasuhiro Kondoh,Arata Azuma,Yoshikazu Inoue,Takashi Ogura,Susumu Sakamoto,Kenji Tsushima,Takeshi Johkoh,Kiminori Fujimoto,Kazuya Ichikado,Yasuo Matsuzawa,Takefumi Saito,Kazuma Kishi,Keisuke Tomii,Noriho Sakamoto,Masahiro Aoshima,Jun Araya,Shinyu Izumi,Machiko Arita,Mitsuhiro Abe,Hiroyoshi Yamauchi,Joe Shindoh,Takafumi Suda,Masaki Okamoto,Masahito Ebina,Yoshihito Yamada,Yuji Tohda,Tetsuji Kawamura,Yoshio Taguchi,Hiroshi Ishii,Naozumi Hashimoto,Shinji Abe,Hiroyuki Taniguchi,Jun Tagawa,Koji Bessho,Natsuki Yamamori,Sakae Homma

Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial

2020

Rationale: Acute exacerbation during the course of idiopathic pulmonary fibrosis causes a poor prognosis. Coagulation abnormalities and endothelial damage are involved in its pathogenesis. Thrombom...

Keywords:

Idiopathic pulmonary fibrosis
Gastroenterology
Thrombomodulin
Anesthesia
Placebo-controlled study
Internal medicine
Clinical trial
Pathogenesis
Diabetes mellitus
Medicine
Exacerbation
Thrombomodulin Alfa

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations